The Pfizer logo on the lab coat of an employee at the company's research and development facility in Cambridge, Massachusetts. | Bloomberg
The Pfizer logo on the lab coat of an employee at the company's research and development facility in Cambridge, Massachusetts. | Bloomberg
Text Size:

London: The U.S. agreed to pay $1.95 billion for 100 million doses of a vaccine made by Pfizer Inc. and BioNTech SE, the government’s latest step to lock up supplies to fight the pandemic.

The U.S. will pay the companies when it receives the doses, following regulatory authorization or approval, according to a statement Wednesday. The government also can acquire up to an additional 500 million doses.

Pfizer shares rose more than 5% in pre-market trading. BioNTech climbed about 5%.

Nations around the world have begun ordering vaccines that are still being tested as part of their efforts to try to blunt the impact of the pandemic that’s roiled economies and killed more than 600,000 people since the beginning of the year. The U.S. has already ordered experimental shots including one co-developed by the University of Oxford and AstraZeneca Plc.

Calculating price

Assuming the deal for the Pfizer-BioNTech vaccine is for the first 100 million doses, that suggests a price of $20 per dose, according to Sam Fazeli, a Bloomberg Intelligence analyst.

“If this vaccine prevents disease after one use, we calculate a windfall of more than $15 billion revenue for Pfizer,” he said in a note. “We believe this sets the top price for a vaccine, with lower prices elsewhere. Need for repeated use would be the game changer.”

Earlier this week, Tazeen Ahmad, an analyst with BofA, estimated that BioNTech’s vaccine program is worth about $11.7 billion. That’s based on an estimated $36 net price per dose in the U.S., $30 per dose in the European Union and $12 per dose in the rest of the world.

Pricing a Covid vaccine is far different than other products because of the potential demand and value, Pfizer Chief Executive Officer Albert Bourla said in June at a conference.

“If we try to calculate the value of the vaccine for the pricing like any other vaccine,” through common market principles, Bourla said, “it would be unethical.”

Supply concerns

The U.S. deals have stoked concerns that other countries, especially poorer regions of the world, will be left behind. Other rich countries, such as the U.K. and those in Europe, have also secured deals.

The U.S. in May pledged as much as $1.2 billion to AstraZeneca to help make Oxford’s Covid vaccine, and the government has backed projects underway at Johnson & Johnson, Moderna Inc. and other companies.

The Pfizer vaccine would be available to the American people for free, according to the government. The U.S moves are part of a larger initiative to secure coronavirus vaccines for the U.S., officially dubbed Operation Warp Speed.

“Expanding Operation Warp Speed’s diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” Health and Human Services Secretary Alex Azar said in the statement.-Bloomberg


Also read: Covid patients given favipiravir showed ‘40% faster’ recovery, Glenmark trial results claim


 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises.

But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle.

ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here.

Support Our Journalism

VIEW COMMENTS